TrialLancet (London, England)2023

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.

Christopher C Butler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.